A:NYSEAgilent Technologies, Inc. Analysis

Agilent Technologies (A) is trading at $116.64, just above its near‑term support of $113.32 and below the 20‑day SMA of $122.97, while the 50‑day SMA sits at $132.49, indicating a short‑term down‑trend. The RSI of 32.5 suggests the stock is approaching oversold territory, but the MACD remains bearish with the line below the signal, and the MACD histogram is negative. Fundamentals remain solid: revenue grew 7% YoY to $7.06 B, gross margin is 52.3%, operating margin 22.9%, and free cash flow stands at $847 M. The forward EPS of $6.56 implies a forward P/E of 17.8, well below the trailing P/E of 25.7, and the payout ratio is a modest 22% supporting dividend sustainability. However, the DCF‑derived fair value of $49.57 is far below the current price, creating a large valuation gap, and the analyst consensus projects a 40% upside to a target mean of $163.29. Recent news adds mixed signals: Q1 earnings missed estimates despite a 4.4% core revenue growth and the company raised guidance, while the $950 M Biocare Medical acquisition promises new pathology revenue streams. Short interest has risen to 1.54% of float, indicating heightened short‑term pressure.
Overall, the stock shows strong cash generation and growth catalysts, but its current valuation appears stretched relative to intrinsic estimates, and technical indicators point to continued near‑term weakness.